Japan Alzheimers Disease Diagnostics Market Size & Outlook
- Clinical Diagnostics
- In Vitro Diagnostics
- Alzheimers Disease Diagnostics Market Outlook
- In Vitro Diagnostics
Global Market
Related Markets
Ask a question about the alzheimers disease diagnostics market
Japan alzheimers disease diagnostics market highlights
- The Japan alzheimers disease diagnostics market generated a revenue of USD 226.1 million in 2025 and is expected to reach USD 563.4 million by 2033.
- The Japan market is expected to grow at a CAGR of 12.1% from 2026 to 2033.
- In terms of segment, imaging techniques was the largest revenue generating diagnostic technique in 2025.
- Biomarkers is the most lucrative diagnostic technique segment registering the fastest growth during the forecast period.
Alzheimers disease diagnostics market data book summary
| Market revenue in 2025 | USD 226.1 million |
| Market revenue in 2033 | USD 563.4 million |
| Growth rate | 12.1% (CAGR from 2026 to 2033) |
| Largest segment | Imaging techniques |
| Fastest growing segment | Biomarkers |
| Historical data | 2021 - 2024 |
| Base year | 2025 |
| Forecast period | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Biomarkers, Imaging Techniques, Genetic Testing, Cognitive Assessment Tests |
| Key market players worldwide | Quest Diagnostics Inc, Sysmex Corp, Lantheus Holdings Inc, Siemens Healthineers AG ADR, F. Hoffmann-La Roche Ltd., Quanterix, Fujirebio Diagnostics, C2N Diagnostics |
Other key industry trends
- In terms of revenue, Japan accounted for 2.5% of the global alzheimers disease diagnostics market in 2025.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In Asia Pacific, China alzheimers disease diagnostics market is projected to lead the regional market in terms of revenue in 2033.
- India is the fastest growing regional market in Asia Pacific and is projected to reach USD 600.2 million by 2033.
It is anticipated that the Japan market for Alzheimer’s disease diagnostics will expand significantly, attributed to Japan's growing Alzheimer's disease population, which is expected to reach 6-7 million by 2025. This raises the need for early diagnosis and treatment of Alzheimer’s, which is the most common form of dementia, accounting for approximately 60%-70% of all cases.
The elderly (those over 65) make up 20% of the population, making Japan the country with the largest proportion of elderly people worldwide. The age-specific prevalence of Alzheimer’s also contributed to this trend. The increased prevalence of metabolic disorders, such as diabetes and hypercholesterolemia, which have been linked to an increased risk of Alzheimer's, is another possible factor contributing to the rise in the overall prevalence of Alzheimer’s cases.
Furthermore, manufacturers in the region are involved in the development of new assay kits that address the fundamental pathology of Alzheimer’s disease. For instance, in June 2023, in Japan, the HISCL β-Amyloid 1-42 and 1-40 Assay Kit was introduced by Sysmex Corporation.
No credit card required*
Publish Date: Dec 17, 2025
Customize the Report
20% free customization
- Include
- Countries, segments, points
- Tailor
- To your product definition
- Extend
- Deeper competitor detail
- Or
- A fully bespoke study
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Alzheimers Disease Diagnostics Market Scope
Alzheimers Disease Diagnostics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Siemens Healthineers AG ADR | View profile | 71,400 | Siemensstr. 3, Forchheim, BY, Germany, 91301 | www.siemens-healthineers.com |
| Quest Diagnostics Inc | View profile | 48,000 | 500 Plaza Drive, Secaucus, NJ, United States, 07094 | www.questdiagnostics.com |
| Sysmex Corp | View profile | 10,448 | 1-5-1 Wakinohara-Kaigandori, Chuo-ku, Hyogo Prefecture, Kobe, Japan, 6510073 | www.sysmex.co.jp |
| Lantheus Holdings Inc | View profile | 834 | 201 Burlington Road, South Building, Bedford, MA, United States, 01730 | www.lantheus.com |
| F. Hoffmann-La Roche Ltd. | View profile | - | - | - |
| C2N Diagnostics | View profile | 11-50 | Saint Louis, Missouri, United States, North America | c2n.com/ |
| Fujirebio Diagnostics | View profile | 5001-10000 | Malvern, Pennsylvania, United States, North America | www.fdi.com/ |
| Quanterix | View profile | 251-500 | Billerica, Massachusetts, United States, North America | www.quanterix.com |
Japan Alzheimers Disease Diagnostics Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Alzheimers Disease Diagnostics Market Outlook will help companies and investors design strategic landscapes.
Imaging Techniques was the largest segment with a revenue share of 45.25% in 2025.
Horizon Databook has segmented the Japan alzheimers disease diagnostics market based on biomarkers, imaging techniques, genetic testing, cognitive assessment tests covering the revenue growth of each sub-segment from 2021 to 2033.
It is anticipated that the Japan market for Alzheimer’s disease diagnostics will expand significantly, attributed to Japan's growing Alzheimer's disease population, which is expected to reach 6-7 million by 2025. This raises the need for early diagnosis and treatment of Alzheimer’s, which is the most common form of dementia, accounting for approximately 60%-70% of all cases.
The elderly (those over 65) make up 20% of the population, making Japan the country with the largest proportion of elderly people worldwide. The age-specific prevalence of Alzheimer’s also contributed to this trend. The increased prevalence of metabolic disorders, such as diabetes and hypercholesterolemia, which have been linked to an increased risk of Alzheimer's, is another possible factor contributing to the rise in the overall prevalence of Alzheimer’s cases.
Furthermore, manufacturers in the region are involved in the development of new assay kits that address the fundamental pathology of Alzheimer’s disease. For instance, in June 2023, in Japan, the HISCL β-Amyloid 1-42 and 1-40 Assay Kit was introduced by Sysmex Corporation.
- Japan Alzheimers Disease Diagnostics Market Diagnostic Technique Outlook (Revenue, USD Million , 2021-2033)
- Biomarkers
- Imaging Techniques
- Genetic Testing
- Cognitive Assessment Tests
- Japan Alzheimers Disease Diagnostics Market Type Outlook (Revenue, USD Million , 2021-2033)
- Triage
- Diagnosis
- Screening
- Japan Alzheimers Disease Diagnostics Market End Use Outlook (Revenue, USD Million , 2021-2033)
- Hospitals
- Diagnostic Laboratories
- Academic and Research Institutes
Reasons to subscribe to Alzheimers Disease Diagnostics Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Alzheimers Disease Diagnostics Market Outlook databook
- Our clientele includes a mix of Alzheimers Disease Diagnostics Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Japan Alzheimers Disease Diagnostics Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into Japan Alzheimers Disease Diagnostics Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Japan Alzheimers Disease Diagnostics Market, 2021-2033 (US$M)
Japan alzheimers disease diagnostics market statistics, by diagnostic technique, 2021-2033 (US$M)
